# Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

> **NCT04984707** · PHASE1 · COMPLETED · sponsor: **Suzhou Kintor Pharmaceutical Inc,** · enrollment: 40 (actual)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** KX0826
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04984707
- **Lead sponsor:** Suzhou Kintor Pharmaceutical Inc,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-28
- **Primary completion:** 2019-04-11
- **Final completion:** 2019-10-24
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04984707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04984707, "Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04984707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*